All Photos(1)

Documents

Y0001518

Haloperidol for peak identification

Name: Haloperidol for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Haloperidol, 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₁H₂₃ClFNO₂

CAS Number:

52-86-8

Molecular Weight:

375.86

MDL number:

MFCD00051423

UNSPSC Code:

41116107

PubChem Substance ID:

329831469

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

haloperidol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3

InChI

1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

InChI key

LNEPOXFFQSENCJ-UHFFFAOYSA-N

Gene Information

human ... HTR2A(3356)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Haloperidol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1303013

1303057

Haloperidol decanoate, United States Pharmacopeia (USP) Reference Standard

1303024

PHR1724

Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material

BP407

Haloperidol, British Pharmacopoeia (BP) Reference Standard

PHR8951

PHR8714

Pictograms

GHS06,GHS08

Signal Word

Danger

Hazard Statements

H301,H315,H317,H319,H335,H361

Precautionary Statements

P201 - P280 - P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Do antipsychotics prevent postoperative delirium? A systematic review and meta-analysis.

Mark C Fok et al.

International journal of geriatric psychiatry, 30(4), 333-344 (2015-02-03)

To summarize the effect of antipsychotics for preventing postoperative delirium. We conducted a literature search using Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and clinicaltrials.gov. We included randomized controlled trials of adults undergoing surgery

Haloperidol for the treatment of nausea and vomiting in palliative care patients.

Paul Perkins et al.

The Cochrane database of systematic reviews, (2)(2), CD006271-CD006271 (2009-04-17)

Nausea and vomiting are common symptoms of patients with terminal, incurable illnesses and can be distressing. The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of

A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.

Marianne Klemp et al.

Journal of clinical psychopharmacology, 31(6), 698-704 (2011-10-25)

The objective of the study was to examine the efficacy and the degree of adverse effects connected with atypical neuroleptic drugs and haloperidol by using a previously described Bayesian statistical method that includes both direct and indirect comparisons simultaneously. The

Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.

Gerard W K Hugenholtz et al.

The Journal of clinical psychiatry, 67(6), 897-903 (2006-07-20)

To determine the doses of haloperidol as a comparator drug in randomized controlled trials (RCTs) with atypical antipsychotics in patients with schizophrenia and to compare these doses with the officially recommended doses for haloperidol in the United States and the

Acute administration of haloperidol does not influence 123I-FP-CIT binding to the dopamine transporter.

Jan Booij et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(4), 647-649 (2014-03-08)

A recent (123)I-FP-CIT ((123)-I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane) SPECT study on rats suggested that a single 1 mg/kg dose of the antipsychotic haloperidol induces enough dopamine release to compete with (123)I-FP-CIT for binding to the dopamine transporter. Taking into account the far-reaching consequences of

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service